Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1

172MO - Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients

Date

31 Mar 2022

Session

Mini Oral session 1

Topics

Immunotherapy;  Pathology/Molecular Biology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jun Li

Citation

Annals of Oncology (2022) 33 (suppl_2): S111-S116. 10.1016/annonc/annonc866

Authors

J. Li1, J. xu2, C.R. Xia2, P. Luo2, S. Ding2

Author affiliations

  • 1 Shandong Provincial Hospital, Shandong/CN
  • 2 Shanghai Topgen Biomedical Technology, Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

Abstract 172MO

Background

Comutations in DDR related pathways may serve as potential predictors for Immune checkpoint blockades (ICB) therapy, providing a potentially convenient approach for future clinical practice.

Methods

Genomic alterations were determined by OncoDrug-SeqTM603-gene panel assay through next generation sequencing (NGS). Patients who harbored mutations in both homologous recombination repair (HRR) and mismatch repair (MMR) pathways were enrolled in group A. Patients who harbored mutations in only HRR pathway were enrolled in group B. Patients who harbored mutations in only MMR pathway were enrolled in group C.

Results

Totally, samples from 1309 patients were collected for NGS assay, 691patients (52.7%) were found to harbor at least one variant in DDR related pathways. The top 10 genes with high frequency were EGFR (42.2%), TP53(41.6%), FAT3 (28.2%), KMT2C (25.5%), PDE4DIP (25.6%), FAT1 (21.5%), KMT2D (25.5%), OBSL1 (20.8%), SYNE1 (16.3), and ROS1 (5.5%). Complete data were obtained from 687 patients, including 462 tissue samples and 225 blood samples. Correlated results were obtained in both blood samples and tissue samples. Comutation status was associated with both higher TMB and TNB. Among the three groups, group A had the highest TMB (mean value: 8 mut/Mb). In the other two groups, TMB was 6 mut/Mb in group B, and 5.3 mut/Mb in group C (p=0.000016), respectively. TNB in group A (mean value: 5.9 mut/Mb) was the highest among the three groups with significantly statistical difference (p=0.00026) detected in tissue samples. TNB in group A (mean value: 2.7mut/Mb) was the highest among the three groups detected in blood samples, but with no statistical difference. Table: 172MO

TMB sorting A vs B vs C (p=0.000016) TMB sorting A vs B vs C (p=0.000012)
TNB sorting A vs B vs C (p=0.00026) TNB sorting B vs C vs A (p=0.19)
PDL1 sorting C vs B vs A (p=0.003)

Conclusions

We found that pathogenic DDR changes occurred frequently in lung cancer. Patients who harbored comutation in both MMR and HRR had higher levels of TMB and TNB. Our study suggested that mutations in DDR related pathways were worth for further study in its potential for lung cancer.

Legal entity responsible for the study

Shanghai Topgen Biomedical Technology Co., Ltd.

Funding

Has not received any funding.

Disclosure

J. Xu: Other, Personal and Institutional, Full or part-time Employment: Shanghai Topgen Biomedical Technology Co., Ltd. C.R. Xia, S. Ding: Other, Personal, Full or part-time Employment: Shanghai Topgen Biomedical Technology Co., Ltd. P. Luo: Other, Personal, Member of the Board of Directors: Shanghai Topgen Biomedical Technology Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.